



**AGENIX LIMITED**  
7 Durbell Street P.O. Box 391  
Acacia Ridge QLD 4110  
Australia  
Tel : +61 (0)7 3370 6396  
Fax : +61 (0)7 3370 6370  
Website : www.agenix.com



06016343

SEC#82-5258



17 August 2006

US Securities and Exchange Commission  
Attention: Filing Desk  
450 Fifth Street NW  
WASHINGTON DC 20549  
USA

**SUPL**

Dear Sir

**Re: Submission Under Rule 12g3-2(b) - Agenix Limited**

We refer to the attached announcement that was made to the Australian Stock Exchange on 10 August 2006.

We are providing a copy of the announcement by virtue of our requirements under Rule 12g3-2(b).

Yours sincerely

Tony Finn  
Joint Company Secretary

PROCESSED

AUG 28 2006

THOMSON  
FINANCIAL



## Company Announcement

10 August 2006

### US patent granted for ThromboView technology

Agenix has been granted a US patent covering its ThromboView® technology by the US Patent and Trademarks Office.

Other patent applications emanating from the Patent Cooperation Treaty application are under examination in other jurisdictions. The patent also recently issued in Singapore.

“The granting of this patent strengthens our position to support commercialization of the hu3B6 D-dimer antibody in a variety of product formats, the first of which is ThromboView®” said CEO and Managing Director, Mr. Neil Leggett.

The patent offers broad coverage for the use of the humanized D-dimer antibody or antibody fragment with a range of imaging payload agents such as radiopharmaceuticals for functional imaging or more traditional contrast agents associated with other imaging modalities.

The clot-targeting capabilities of hu3B6 are currently being exploited in the ThromboView® product format which utilizes technetium-99m, a common radioisotope used in nuclear medicine, to image blood clots in both the deep veins of the legs and the pulmonary vasculature.

**END**

**For more information contact:**

Mr Neil Leggett  
CEO and Managing Director  
Agenix Limited  
Ph: + 61 7 3370 6313

**Agenix Limited** [ASX: **AGX**, OTC (NASDAQ): **AGXLY**] is a biotechnology company based in Brisbane, Australia. The Company has a strategic focus of growing a pipeline of monoclonal antibody-based products.

Agenix's lead candidate is its high-technology blood clot-imaging agent, ThromboView®, which is currently undergoing human clinical trials in the United States, Canada and Australia. ThromboView® uses radiolabelled antibodies to locate blood clots in the body, and could revolutionise the global clot diagnostic imaging market. ThromboView® is being developed with the assistance of the Australian Federal Government through its START scheme. ThromboView® is a registered trademark of AGEN Biomedical Ltd, a wholly owned subsidiary of the ASX-listed Agenix Limited.

[www.agenix.com](http://www.agenix.com)